NATIONAL HEART CENTRE SINGAPORE

CADENCE and Medera Launch Asia's First Multi-Centre Gene Therapy Trial for Heart Failure in Singapore

- CADENCE and Medera's Sardocor have initiated Asia's first multi-centre gene therapy clinical trial for heart failure, with Singapore being the only site selected outside the United States. - The gene therapy product SRD-001 targets heart failure with reduced ejection fraction (HFrEF) and aims to improve heart muscle function, reduce symptoms, and decrease hospital readmissions. - The trial represents a significant collaboration between Singapore's national heart centers and highlights the country's robust cardiovascular research infrastructure and potential to advance innovative heart failure treatments.